TerminatedPhase 4

A Study of Loco-Regional Liposomal Bupivacaine Injection

Stopped: Lack of funds

United States2 participantsStarted 2023-09-26

Plain-language summary

The purpose of this research is to find out if using liposomal bupivacaine solution (bupivacaine liposome) injections during lower extremity revascularization surgery will lower the amount of narcotic drugs used during and following the procedure.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Those who present for elective lower extremity revascularization. Exclusion Criteria: * Non-English speaking. * Chronic pain. * On opioids greater than 1 weeks. * Allergy to local anesthetics. * Use of spinal or epidural for surgery. * Lack of patient cooperation. * Lontraindication to regional anesthesia. * Vulnerable individuals.

What they're measuring

Postoperative use of narcotics at 12 hours

Timeframe: 12 hours after injection

Postoperative use of narcotics at 24 hours

Timeframe: 24 hours after injection

Postoperative use of narcotics at 48 hours

Timeframe: 48 hours after injection

Postoperative use of narcotics at 72 hours

Timeframe: 72 hours after injection

Postoperative use of narcotics at 30 days

Timeframe: 30 days after injection

Trial details

NCT IDNCT05992896

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-15

View on ClinicalTrials.gov More Peripheral Arterial Disease trials